➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Dow
Johnson and Johnson
McKesson
Boehringer Ingelheim

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ONIVYDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Onivyde

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02231723 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer Recruiting Boston Biomedical, Inc Phase 1 2014-08-01 This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
NCT02631733 Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended National Cancer Institute (NCI) Phase 1 2016-07-01 This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors that have spread to other parts of the body (metastatic) or cannot be removed by surgery. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02785068 Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer Recruiting Merrimack Pharmaceuticals Phase 1/Phase 2 2016-07-01 A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
NCT03088813 Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer Not yet recruiting Ipsen Phase 3 2017-04-01 This is an open-label phase 3 comparative study to assess the safety, tolerability, and efficacy of irinotecan liposome injection compared to topotecan (IV) in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy. The study will be conducted in two parts: 1a. dose determination of irinotecan liposome injection 1b. preliminary safety and efficacy 2. a randomized, efficacy study of irinotecan liposome injection versus topotecan
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Onivyde

Condition Name

Condition Name for Onivyde
Intervention Trials
Metastatic Pancreatic Adenocarcinoma 4
Pancreatic Adenocarcinoma 3
Stage IV Pancreatic Cancer AJCC v8 2
Pancreatic Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Onivyde
Intervention Trials
Pancreatic Neoplasms 11
Adenocarcinoma 10
Carcinoma 6
Lung Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Onivyde

Trials by Country

Trials by Country for Onivyde
Location Trials
United States 41
Korea, Republic of 2
United Kingdom 2
Taiwan 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Onivyde
Location Trials
Arizona 5
Washington 4
New York 3
California 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Onivyde

Clinical Trial Phase

Clinical Trial Phase for Onivyde
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 10
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Onivyde
Clinical Trial Phase Trials
Not yet recruiting 16
Recruiting 9
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Onivyde

Sponsor Name

Sponsor Name for Onivyde
Sponsor Trials
National Cancer Institute (NCI) 6
Ipsen 5
Merrimack Pharmaceuticals 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Onivyde
Sponsor Trials
Other 28
Industry 17
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
Harvard Business School
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.